Trial Profile
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adult Patients With Schizophrenia or Bipolar Disorder and Recent Weight Gain While Taking Antipsychotic Medications (GRATITUDE)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Feb 2023
Price :
$35
*
At a glance
- Drugs Miricorilant (Primary)
- Indications Weight gain
- Focus Adverse reactions; Therapeutic Use
- Acronyms GRATITUDE; GRATITUDE I
- Sponsors Corcept Therapeutics
- 06 Feb 2023 Status changed from active, no longer recruiting to completed.
- 08 Dec 2022 According to a Corcept Therapeutics media release, data from this study will present at a medical conference next year
- 02 May 2022 Planned End Date changed from 1 Jun 2022 to 1 Jul 2022.